Menlo Park, USA
Expertise: Venture Capital, Venture Growth, Pharmaceutical co-development
Ken has spent 25 years in the management of both early-stage and public high technology and biotechnology companies. Ken's role is to identify, invest in and provide support for portfolio companies. His current and past directorships include eFFECTOR, Gynesonics, Intellikine, SFJ Pharmaceuticals and Zogenix.
He was part of the founding management team at IntelliGenetics, one of the world’s first bioinformatics companies and CEO of IntelliCorp, a publicly-traded enterprise software company. At the beginning of his career he practised as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe, and has been Co-Chair of the Advisory Council to the Neuroscience Institute at Stanford. He received his BA from Harvard College, an MA from the University of Sussex and a JD from Harvard Law School.